Loading page
Loading page
Loading substance route
Extremely potent; onset highly variable (15-240 minutes reported). Heavy doses associated with severe prolonged agitation, paranoia, and hallucinations.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
High abuse potential with significant risk of psychological dependence. Compulsive redosing is commonly reported due to the subtle nature of stimulation, leading users to consume dangerous amounts. Addiction develops at a higher rate than with most other stimulants.
Physical dependence can develop with chronic use. Cravings and withdrawal effects including anxiety, depression, cognitive fatigue, and irritability may occur upon cessation.
Blood plasma concentrations above 600 μg/L have been associated with acute overdose. One case report documents near-fatal ingestion of approximately 1 gram requiring emergency benzodiazepine sedation. Fatalities have been reported, particularly with branded products (e.g., Ivory Wave) where accurate dosing was difficult.
Chronic abuse or overdose can cause prolonged neurotoxic effects including severe agitation lasting up to 5 days and myoclonus; long-term heavy use may lead to persistent dopamine receptor downregulation.
Chest pain and tachycardia have been reported at relatively high rates; however, overall cardiovascular stimulation at typical doses may be milder than with many other stimulants.
Desoxypipradrol triggers psychosis at a significantly higher rate than other stimulants, with an uncommonly low threshold. Both chronic abuse and single-exposure overdose can induce psychotic states. Symptoms include auditory and visual hallucinations, paranoid delusions, mania, grandiosity, severe confusion, increased aggression, and urges toward self-harm. Psychotic episodes may persist for up to 5 days after drug use.
Desoxypipradrol was developed by the pharmaceutical company Ciba (now Novartis) during the 1950s. The compound was initially investigated for therapeutic applications including the treatment of narcolepsy and attention deficit hyperactivity disorder, and was marketed in Germany under the trade name…
Classified as a controlled substance as of October 2015 under national drug control legislation.
Listed as a prohibited substance in Schedule I under the designation (Пиперидин-2-ил)дифенилметан (piperidine-2-yl diphenylmethane).
Import ban implemented November 4, 2010 following an ACMD recommendation citing serious harms including prolonged agitation lasting up to 5 days, paranoia, hallucinations, and myoclonus. Classified as a Class B drug and placed in Schedule I on June 13, 2012 under a blanket ban covering related chemical structures. Esters and ethers of pipradrol were controlled as Class C drugs under the same amendment.
Controlled under Anlage II of the Betäubungsmittelgesetz (Narcotics Act, Schedule II) since December 13, 2014. Manufacturing, possession, import, export, buying, selling, procuring, or dispensing without a license is prohibited.
Not listed under Buchstabe A, B, C, or D of controlled substances legislation. May be considered legal to possess.
Not federally scheduled and therefore legal to possess and import. However, as a structural analog of pipradrol (a Schedule IV controlled substance), prosecution under the Federal Analogue Act may be possible if sold or distributed for human consumption.
14 sources cited